Gene Expression Profiling of Olfactory Neuroblastoma Helps Identify Prognostic Pathways and Define Potentially Therapeutic Targets
Olfactory neuroblastoma (ONB) is a rare sinonasal neoplasm with a peculiar behavior, for which limited prognostic factors are available. Herein, we investigate the transcriptional pathways altered in ONB and correlate them with pathological features and clinical outcomes. We analyze 32 ONB patients treated with curative intent at two independent institutions from 2001 to 2019 for whom there is available pathologic and clinical data. We perform gene expression profiling on primary ONB samples and carry out functional enrichment analysis to investigate the key pathways associated with disease-free survival (DFS). The median age is 53.5 years; all patients undergo surgery and a pure endoscopic approach is adopted in the majority of cases (81.2%). Most patients have advanced disease (stages III-IV, 81.2%) and 84.4% undergo adjuvant (chemo)radiotherapy. The median follow-up is 35 months; 11 (26.8%) patients relapse. Clinical characteristics (gender, stage and Hyams' grade) are not associated with the outcomes. In contrast, TGF-beta binding, EMT, IFN-alpha response, angiogenesis, IL2-STAT5 and IL6-JAK-STAT3 signaling pathways are enriched in patients experiencing recurrence, and significantly associated with shorter DFS. Clustering of transcriptional profiles according to pathological features indicates two distinct molecular groups, defined by either cytokeratin-positive or -negative immunostaining. Definition of the characterizing ONB transcriptomic pathways may pave the way towards tailored treatment approaches.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Cancers - 13(2021), 11 vom: 21. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Romani, Chiara [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Gene expression |
|---|
| Anmerkungen: |
Date Revised 15.06.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers13112527 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326125035 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326125035 | ||
| 003 | DE-627 | ||
| 005 | 20231225193923.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers13112527 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1087.xml |
| 035 | |a (DE-627)NLM326125035 | ||
| 035 | |a (NLM)34064009 | ||
| 035 | |a (PII)2527 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Romani, Chiara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Gene Expression Profiling of Olfactory Neuroblastoma Helps Identify Prognostic Pathways and Define Potentially Therapeutic Targets |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.06.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Olfactory neuroblastoma (ONB) is a rare sinonasal neoplasm with a peculiar behavior, for which limited prognostic factors are available. Herein, we investigate the transcriptional pathways altered in ONB and correlate them with pathological features and clinical outcomes. We analyze 32 ONB patients treated with curative intent at two independent institutions from 2001 to 2019 for whom there is available pathologic and clinical data. We perform gene expression profiling on primary ONB samples and carry out functional enrichment analysis to investigate the key pathways associated with disease-free survival (DFS). The median age is 53.5 years; all patients undergo surgery and a pure endoscopic approach is adopted in the majority of cases (81.2%). Most patients have advanced disease (stages III-IV, 81.2%) and 84.4% undergo adjuvant (chemo)radiotherapy. The median follow-up is 35 months; 11 (26.8%) patients relapse. Clinical characteristics (gender, stage and Hyams' grade) are not associated with the outcomes. In contrast, TGF-beta binding, EMT, IFN-alpha response, angiogenesis, IL2-STAT5 and IL6-JAK-STAT3 signaling pathways are enriched in patients experiencing recurrence, and significantly associated with shorter DFS. Clustering of transcriptional profiles according to pathological features indicates two distinct molecular groups, defined by either cytokeratin-positive or -negative immunostaining. Definition of the characterizing ONB transcriptomic pathways may pave the way towards tailored treatment approaches | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a gene expression | |
| 650 | 4 | |a molecular profiling | |
| 650 | 4 | |a olfactory neuroblastoma | |
| 650 | 4 | |a prognosis | |
| 700 | 1 | |a Bignotti, Eliana |e verfasserin |4 aut | |
| 700 | 1 | |a Mattavelli, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Bozzola, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Lorini, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Tomasoni, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Ardighieri, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Rampinelli, Vittorio |e verfasserin |4 aut | |
| 700 | 1 | |a Paderno, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Battocchio, Simonetta |e verfasserin |4 aut | |
| 700 | 1 | |a Gurizzan, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Castelnuovo, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Turri-Zanoni, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Facco, Carla |e verfasserin |4 aut | |
| 700 | 1 | |a Sessa, Fausto |e verfasserin |4 aut | |
| 700 | 1 | |a Schreiber, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrari, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Ravaggi, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Deganello, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Nicolai, Piero |e verfasserin |4 aut | |
| 700 | 1 | |a Buglione, Michela |e verfasserin |4 aut | |
| 700 | 1 | |a Tomasini, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Maroldi, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Piazza, Cesare |e verfasserin |4 aut | |
| 700 | 1 | |a Calza, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Bossi, Paolo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 13(2021), 11 vom: 21. Mai |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:11 |g day:21 |g month:05 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers13112527 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |e 11 |b 21 |c 05 | ||